314 related articles for article (PubMed ID: 16758262)
1. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
Backman JT; Granfors MT; Neuvonen PJ
Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
[TBL] [Abstract][Full Text] [Related]
2. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
Granfors MT; Backman JT; Laitila J; Neuvonen PJ
Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
[TBL] [Abstract][Full Text] [Related]
4. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
Backman JT; Karjalainen MJ; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Sep; 62(3):345-57. PubMed ID: 16934051
[TBL] [Abstract][Full Text] [Related]
5. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
[TBL] [Abstract][Full Text] [Related]
6. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
Backman JT; Schröder MT; Neuvonen PJ
Eur J Clin Pharmacol; 2008 Jan; 64(1):17-24. PubMed ID: 17955229
[TBL] [Abstract][Full Text] [Related]
7. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.
Karjalainen MJ; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2007 Sep; 63(9):829-36. PubMed ID: 17618427
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.
Karjalainen MJ; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2008 May; 64(5):511-9. PubMed ID: 18197403
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampicin on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.
Schmider J; Brockmöller J; Arold G; Bauer S; Roots I
Pharmacogenetics; 1999 Dec; 9(6):725-34. PubMed ID: 10634135
[TBL] [Abstract][Full Text] [Related]
11. Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine.
Peltoniemi MA; Saari TI; Hagelberg NM; Laine K; Kurkinen KJ; Neuvonen PJ; Olkkola KT
Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):325-32. PubMed ID: 22676424
[TBL] [Abstract][Full Text] [Related]
12. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
13. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
Chen Y; Xiao P; Ou-Yang DS; Fan L; Guo D; Wang YN; Han Y; Tu JH; Zhou G; Huang YF; Zhou HH
Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):828-33. PubMed ID: 19215233
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole weakly inhibits CYP1A2 activity in man.
Rost KL; Fuhr U; Thomsen T; Zaigler M; Brockmöller J; Bohnemeier H; Roots I
Int J Clin Pharmacol Ther; 1999 Nov; 37(11):567-74. PubMed ID: 10584979
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
Britz H; Hanke N; Volz AK; Spigset O; Schwab M; Eissing T; Wendl T; Frechen S; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):296-307. PubMed ID: 30762305
[TBL] [Abstract][Full Text] [Related]
18. [The combined effect of isoniazid and rifampicin on the activities of CYP4501A2 and CYP4503A4 in primary hepatocytes from healthy human adults].
Liu ZW; Hu ZH; Cai YY
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Nov; 28(11):785-8. PubMed ID: 16324277
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin.
Kivistö KT; Villikka K; Nyman L; Anttila M; Neuvonen PJ
Clin Pharmacol Ther; 1998 Dec; 64(6):648-54. PubMed ID: 9871429
[TBL] [Abstract][Full Text] [Related]
20. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4.
Lilja JJ; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2007 Jun; 81(6):833-9. PubMed ID: 17392729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]